How do monoclonal antibodies protect babies from RSV?
Monoclonal antibodies are lab-made proteins that act like a ready-made immune system. Instead of waiting for a baby's body to build its own defenses (which takes weeks and may not be strong enough), a single injection delivers a high dose of antibodies that immediately neutralize the RSV virus. For example, nirsevimab—the most studied antibody here—raised infants' neutralizing antibody levels more than 140-fold above baseline within a month, and those levels stayed more than 50-fold higher at 5 months, covering an entire RSV season [3]. This is a fundamentally different approach from a vaccine, which teaches the body to make its own antibodies over time.
The key advantage is speed and reliability. In a large network meta-analysis of 15 trials involving over 18,000 infants, nirsevimab, palivizumab, and motavizumab all significantly reduced RSV infections and hospitalizations without increasing side effects [1]. A newer antibody, clesrovimab, showed similar promise in a phase 2b/3 trial of 3,632 infants, reducing RSV-associated medically attended lower respiratory tract infections by 60% and hospitalizations by 84% over 150 days [2]. These antibodies are designed to be given as a single dose before or during RSV season.
How effective are they at preventing severe RSV?
Very effective, especially against the outcomes that matter most: hospitalization and severe illness. The network meta-analysis found that, compared with placebo, nirsevimab prevented about 54 RSV-related hospitalizations per 1,000 infants, and palivizumab prevented about 39 per 1,000 [1]. That means for every 1,000 babies who get nirsevimab, roughly 54 fewer will end up in the hospital for RSV than if they got nothing. The same study also showed that nirsevimab reduced the need for supplemental oxygen by 59 per 1,000 infants [1].
The clesrovimab trial went further, showing that protection increased with disease severity: it cut severe RSV cases (those needing intensive care or mechanical ventilation) by 92% [2]. This pattern—stronger protection against more serious illness—is exactly what parents and doctors want. Real-world data from Spain, where nirsevimab was rolled out to all infants in one region, backs this up: uptake reached 97.5% in high-risk infants and 92.6% in newborns, and early reports showed a major public health benefit [6]. By the 2023-2024 season in the U.S., about 19% of infants had received nirsevimab, though coverage varied widely by state [4].
Are they safe for my baby?
Yes, the evidence consistently shows these antibodies are safe and well-tolerated. In the largest analysis, there were no significant differences in drug-related adverse events or all-cause mortality between infants who received monoclonal antibodies and those who got a placebo [1]. The clesrovimab trial reported that the proportion of infants with adverse events—including injection-site reactions, systemic side effects, and serious adverse events—was comparable between the antibody and placebo groups, and there were no treatment-related deaths [2].
Even when used as a treatment for active RSV bronchiolitis (rather than prevention), a randomized trial of 420 infants found that intravenous palivizumab did not cause harm—it simply didn't help treat existing illness, which is why these antibodies are recommended only for prevention [5]. For prevention, the safety record is strong across multiple antibodies and thousands of infants.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2019 to 2025, 2 from 2024 or later, 3 in Q1 journals, collectively cited 289 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 59 papers retrieved from a database of over 500 million.
Sources used in this answer
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children
A network meta-analysis of 15 RCTs (18,395 participants) found that nirsevimab, palivizumab, and motavizumab significantly reduced RSV infections and hospitalizations without increasing adverse events; nirsevimab reduced hospitalizations by 54 per 1,000 infants.
166. A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants
A phase 2b/3 RCT of 3,632 infants found that a single dose of clesrovimab reduced RSV-associated medically attended lower respiratory tract infections by 60% and hospitalizations by 84% over 150 days, with a safety profile comparable to placebo.
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Analysis of serum from 2,143 infants in nirsevimab trials showed that nirsevimab provided >140-fold higher neutralizing antibody levels at day 31, sustained >50-fold at day 151, and allowed natural immune response to RSV without blocking it.
Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination — United States, October 2023–March 2024
U.S. surveillance data from 33 states and DC estimated that 29% of infants born October 2023–March 2024 were immunized against RSV (19% via nirsevimab, 10% via maternal vaccine), with state-level coverage ranging from 11% to 53%.
Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial.
A randomized trial of 420 infants with acute RSV bronchiolitis found that intravenous palivizumab did not reduce readmission rates or improve outcomes compared to placebo, confirming it is not effective as a treatment.
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
A real-world implementation report from Galicia, Spain, showed that a 3-week hospital-based campaign achieved nirsevimab uptake of 97.5% in high-risk infants, 81.4% in catch-up groups, and 92.6% in newborns.